Table 1.

Comparison of SWOG 99-16 and TAX 327 Data

Trial	SWOG 99-16	SWOG 99-16	TAX 327	TAX 327	TAX 327
Regimen	D+E+D	M+P	D3P	D1P	MP
Median age (y)	70	70	68	69	68
Visceral disease (n)	18	19	22	24	22
Median PSA	84	90	114	108	123
score (ng/mL)
Median survival (mo)	17.5	15.6	18.9	17.4	16.5
≥ 50% decline in	50	27	45	48	32
serum PSA level (%)

SWOG, Southwest Oncology Group; D+E+D, docetaxel, estramustine, and dexamethasone; M+P, mitoxantrone and prednisone; D3P, every-3-week docetaxel and prednisone; D1P, weekly docetaxel and prednisone; MP, mitoxantrone and prednisone; PSA, prostate-specific antigen. Data from Tannock IF et al and Petrylak DP et al.²,³